MBX Biosciences, Inc. today announced positive results from the multiple ascending dose (MAD) portion of the Phase 1 trial of MBX 2109.
Stealth BioTherapeutics Inc. today announced its achievement of target enrollment in the NuPOWER (SPIMD-301) study in patients with primary mitochondrial myopathy (PMM).
Sumitomo Pharma Co., Ltd. companies, Sumitomo Pharma America, Inc. (SMPA) and Sumitomo Pharma Switzerland (SMPS), announced today that the Phase 3 URO-901-3005 clinical study of vibegron.
BioLineRx Ltd. (NASDAQ/TASE: BLRX), a commercial stage biopharmaceutical company focused on certain cancers and rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved APHEXDA.
Bristol Myers Squibb (NYSE: BMY) today announced six-year results from Part 1 of the Phase 3 CheckMate -227 trial, which continues to demonstrate long-term, durable survival benefits of Opdivo (nivolumab) plus Yervoy (ipilimumab) compared to chemotherapy in the first-line treatment of patients with metastatic non-small cell lung cancer.
Blue Earth Therapeutics Announces Promising Results of Preclinical Evaluation of 225 Ac-rhPSMA-10.1 for Potential Targeted Alpha Therapy of Prostate Cancer.
Solu Therapeutics, a precision-medicine company developing therapeutics to eliminate disease-driving cells, today announced the appointment of Philip J. Vickers, Ph.D., as President and Chief Executive Officer.
Results from the primary analysis of the DESTINY-Lung02 phase 2 trial showed ENHERTU® continued to demonstrate strong and durable tumor responses in previously treated patients with HER2 mutant unresectable and/or metastatic non-squamous non-small cell lung cancer.
AVM Biotechnology, a clinical stage company enrolling Phase 2 adaptive design/expansion cohorts for immunomodulatory AVM0703 in relapsed/refractory Non-Hodgkin Lymphoma/Leukemia patients, will present at the Bio Investor Forum, held in San Francisco, CA October 17-18, 2023.
Orano Med SAS, “Orano Med”, a biotechnology company developing Lead-212 Targeted Alpha Therapy against cancer, and Orbit Discovery Ltd, “Orbit”, a leader in the discovery of therapeutic peptide hits, announced that they have entered into a collaboration to discover specific Peptide Receptor Radionuclide Therapies against cancer cells and advance the development of novel radiopharmaceuticals.
